Impacts of the STING‐IFNAR1‐STAT1‐IRF1 pathway on the cellular immune reaction induced by fractionated irradiation-Reference-Cited by-同舟云学术

Impacts of the STING‐IFNAR1‐STAT1‐IRF1 pathway on the cellular immune reaction induced by fractionated irradiation

Published:2022-02-20 Issue:4 Volume:113 Page:1352-1361
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Du Junyan¹²^ORCID,Kageyama Shun‐Ichiro³⁴,Yamashita Riu¹,Hirata Hidenari³⁴,Hakozaki Yumi⁴,Okumura Masayuki³,Motegi Atsushi³,Hojo Hidehiro³,Nakamura Masaki³,Hirano Yasuhiro³,Sunakawa Hironori⁵,Minamide Tatsunori⁵,Kotani Daisuke⁶,Tanaka Kosuke⁷,Yano Tomonori⁵,Kojima Takashi⁶^ORCID,Ohashi Akihiro⁷,Tsuchihara Katsuya¹²^ORCID,Akimoto Tetsuo³⁴

Affiliation:

1. Division of Translational Informatics Exploratory Oncology Research and Clinical Trial Center National Cancer Center Chiba Japan

2. Department of Integrated Biosciences Graduate School of Frontier Sciences The University of Tokyo Chiba Japan

3. Division of Radiation Oncology and Particle Therapy National Cancer Center Hospital East Chiba Japan

4. Department of Radiation Oncology National Cancer Center Hospital East Chiba Japan

5. Department of Gastroenterology and Endoscopy National Cancer Center Hospital East Chiba Japan

6. Department of Gastroenterology and Gastrointestinal Oncology National Cancer Center Hospital East Chiba Japan

7. Division of Translational Research Exploratory Oncology Research and Clinical Trial Center National Cancer Center Chiba Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15297

Reference27 articles.

1. Cancer and Radiation Therapy: Current Advances and Future Directions

2. Strategies to improve radiotherapy with targeted drugs

3. New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology

4. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

5. Inflammatory microenvironment remodelling by tumour cells after radiotherapy

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PARP7-mediated ADP-ribosylation of FRA1 promotes cancer cell growth by repressing IRF1- and IRF3-dependent apoptosis;Proceedings of the National Academy of Sciences;2023-11-27

2. Opportunities and challenges in combining immunotherapy and radiotherapy in esophageal cancer;Journal of Cancer Research and Clinical Oncology;2023-11-20

3. Ferroptosis triggered by STAT1- IRF1-ACSL4 pathway was involved in radiation-induced intestinal injury;Redox Biology;2023-10

4. Transposable elements potentiate radiotherapy-induced cellular immune reactions via RIG-I-mediated virus-sensing pathways;Communications Biology;2023-08-05

5. Regulation of IFNβ expression: focusing on the role of its promoter and transcription regulators;Frontiers in Microbiology;2023-06-15